Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new analysis of its Phase 3 SCORED clinical trial demonstrating the protective effects of sotagliflozin in patients with diabetic kidney ...
Measures of glycemia and lipemia improved more in the intervention group. Conclusions: The intensive lifestyle intervention produced long-term beneficial changes in diet, physical activity ...